Global Refractory Multiple Myeloma Treatment Market
Global Refractory Multiple Myeloma Treatment Market

Refractory Multiple Myeloma Treatment Comprehensive Study by Type (Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib), Cytotoxic agents, High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT), Allogeneic Stem Cell Transplantation), Distribution Channel (Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Others), Drug Class (Proteasome Inhibitor, Anti-CD38 Monoclonal Antibody, Alkylating Agents, Others) Players and Region - Global Market Outlook to 2026

Refractory Multiple Myeloma Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 239 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Multiple myeloma is a malignant plasma cell disease that mostly affects secondary organs such as the bone, kidney, and bone marrow, as well as immune and neurologic dysfunction. Multiple myeloma is a clonal plasma cell cancer caused by complex interactions between bone marrow stromal cells, malignant progenitor cells, and the microenvironment of the bone marrow. Refractory multiple myeloma is characterized as a disease that is progressing or non-responsive to therapy, or is progressing or non-responsive within sixty days of the last treatment in patients with a poor response. The increasing prevalence of multiple myeloma, advancement in research and development for innovative therapeutics for refractory multiple myeloma treatment, and the introduction of monoclonal antibodies for refractory multiple myeloma treatment are some of the factors driving the growth of the refractory multiple myeloma treatment market.This growth is primarily driven by Increased Prevalence of numerous forms of Blood Cancers and Increased need for efficient and effective treatments or Rare Diseases.

Major Players, such as Takeda Pharmaceutical Company Limited (Japan), Novartis AG (Switzerland), GlaxoSmithKline Plc (United Kingdom), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (Unite States), Amgen Inc. (United States), ONO PHARMACEUTICAL CO., LTD. (Japan), Janssen Pharmaceuticals, Inc. (United States), AbbVie Inc (United States) and Sanofi (France) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

August 2020 – GlaxoSmithKline Plc announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamabmafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma, and March 2020 – Sanofi - The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Market Drivers
  • Increased Prevalence of numerous forms of Blood Cancers
  • Increased need for efficient and effective treatments or Rare Diseases

Market Trend

Restraints
  • Lack of R&D as it is a rare disease
  • High Cost of Treatment

Opportunities
Advancement in Research and Development for Innovative Therapeutics
Challenges
Lack of Effective Treatments in Certain Countries and Lack of Awareness Among People

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
AMA Research & Media features not only specific market forecasts, but also include significant value-added commentary on:
Market Trends
Technological Trends and Innovations
Regulatory Trends & Policies
Market Maturity Indicators
Market Share Movements
Growth Drivers and Constraints
New Entrants into the Market & Entry/Exit Barriers
Consumer Demographics
Supporting Company Financial and Cash Flow Planning
Open Up New Markets
To Seize Powerful Market Opportunities
Key Decision in Planning and to Further Expand Market Share
Identify Key Business Segments, Market Proposition & Gap Analysis
Report Objectives / Segmentation Covered
By Type
  • Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib)
  • Cytotoxic agents
  • High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT)
  • Allogeneic Stem Cell Transplantation
By Distribution Channel
  • Hospitals
  • Cancer Institutes
  • Ambulatory Surgical Centers
  • Others

By Drug Class
  • Proteasome Inhibitor
  • Anti-CD38 Monoclonal Antibody
  • Alkylating Agents
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of numerous forms of Blood Cancers
      • 3.2.2. Increased need for efficient and effective treatments or Rare Diseases
    • 3.3. Market Challenges
      • 3.3.1. Lack of Effective Treatments in Certain Countries
      • 3.3.2. Lack of Awareness Among People
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Refractory Multiple Myeloma Treatment, by Type, Distribution Channel, Drug Class and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Refractory Multiple Myeloma Treatment (Value)
      • 5.2.1. Global Refractory Multiple Myeloma Treatment by: Type (Value)
        • 5.2.1.1. Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib)
        • 5.2.1.2. Cytotoxic agents
        • 5.2.1.3. High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT)
        • 5.2.1.4. Allogeneic Stem Cell Transplantation
      • 5.2.2. Global Refractory Multiple Myeloma Treatment by: Distribution Channel (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Cancer Institutes
        • 5.2.2.3. Ambulatory Surgical Centers
        • 5.2.2.4. Others
      • 5.2.3. Global Refractory Multiple Myeloma Treatment by: Drug Class (Value)
        • 5.2.3.1. Proteasome Inhibitor
        • 5.2.3.2. Anti-CD38 Monoclonal Antibody
        • 5.2.3.3. Alkylating Agents
        • 5.2.3.4. Others
      • 5.2.4. Global Refractory Multiple Myeloma Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Refractory Multiple Myeloma Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol Myers Squibb Company (Unite States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amgen Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ONO PHARMACEUTICAL CO., LTD. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Janssen Pharmaceuticals, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AbbVie Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Refractory Multiple Myeloma Treatment Sale, by Type, Distribution Channel, Drug Class and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Refractory Multiple Myeloma Treatment (Value)
      • 7.2.1. Global Refractory Multiple Myeloma Treatment by: Type (Value)
        • 7.2.1.1. Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib)
        • 7.2.1.2. Cytotoxic agents
        • 7.2.1.3. High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT)
        • 7.2.1.4. Allogeneic Stem Cell Transplantation
      • 7.2.2. Global Refractory Multiple Myeloma Treatment by: Distribution Channel (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Cancer Institutes
        • 7.2.2.3. Ambulatory Surgical Centers
        • 7.2.2.4. Others
      • 7.2.3. Global Refractory Multiple Myeloma Treatment by: Drug Class (Value)
        • 7.2.3.1. Proteasome Inhibitor
        • 7.2.3.2. Anti-CD38 Monoclonal Antibody
        • 7.2.3.3. Alkylating Agents
        • 7.2.3.4. Others
      • 7.2.4. Global Refractory Multiple Myeloma Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Refractory Multiple Myeloma Treatment: by Type(USD Million)
  • Table 2. Refractory Multiple Myeloma Treatment Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib) , by Region USD Million (2015-2020)
  • Table 3. Refractory Multiple Myeloma Treatment Cytotoxic agents , by Region USD Million (2015-2020)
  • Table 4. Refractory Multiple Myeloma Treatment High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT) , by Region USD Million (2015-2020)
  • Table 5. Refractory Multiple Myeloma Treatment Allogeneic Stem Cell Transplantation , by Region USD Million (2015-2020)
  • Table 6. Refractory Multiple Myeloma Treatment: by Distribution Channel(USD Million)
  • Table 7. Refractory Multiple Myeloma Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 8. Refractory Multiple Myeloma Treatment Cancer Institutes , by Region USD Million (2015-2020)
  • Table 9. Refractory Multiple Myeloma Treatment Ambulatory Surgical Centers , by Region USD Million (2015-2020)
  • Table 10. Refractory Multiple Myeloma Treatment Others , by Region USD Million (2015-2020)
  • Table 11. Refractory Multiple Myeloma Treatment: by Drug Class(USD Million)
  • Table 12. Refractory Multiple Myeloma Treatment Proteasome Inhibitor , by Region USD Million (2015-2020)
  • Table 13. Refractory Multiple Myeloma Treatment Anti-CD38 Monoclonal Antibody , by Region USD Million (2015-2020)
  • Table 14. Refractory Multiple Myeloma Treatment Alkylating Agents , by Region USD Million (2015-2020)
  • Table 15. Refractory Multiple Myeloma Treatment Others , by Region USD Million (2015-2020)
  • Table 16. South America Refractory Multiple Myeloma Treatment, by Country USD Million (2015-2020)
  • Table 17. South America Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 18. South America Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 19. South America Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 20. Brazil Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 21. Brazil Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 22. Brazil Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 23. Argentina Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 24. Argentina Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 25. Argentina Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 26. Rest of South America Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 27. Rest of South America Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 28. Rest of South America Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 29. Asia Pacific Refractory Multiple Myeloma Treatment, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 31. Asia Pacific Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 32. Asia Pacific Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 33. China Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 34. China Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 35. China Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 36. Japan Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 37. Japan Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 38. Japan Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 39. India Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 40. India Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 41. India Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 42. South Korea Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 43. South Korea Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 44. South Korea Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 45. Taiwan Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 46. Taiwan Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 47. Taiwan Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 48. Australia Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 49. Australia Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 50. Australia Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 54. Europe Refractory Multiple Myeloma Treatment, by Country USD Million (2015-2020)
  • Table 55. Europe Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 56. Europe Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 57. Europe Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 58. Germany Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 59. Germany Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 60. Germany Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 61. France Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 62. France Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 63. France Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 64. Italy Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 65. Italy Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 66. Italy Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 67. United Kingdom Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 68. United Kingdom Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 69. United Kingdom Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 70. Netherlands Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 71. Netherlands Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 72. Netherlands Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 73. Rest of Europe Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 74. Rest of Europe Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 75. Rest of Europe Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 76. MEA Refractory Multiple Myeloma Treatment, by Country USD Million (2015-2020)
  • Table 77. MEA Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 78. MEA Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 79. MEA Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 80. Middle East Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 81. Middle East Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 82. Middle East Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 83. Africa Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 84. Africa Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 85. Africa Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 86. North America Refractory Multiple Myeloma Treatment, by Country USD Million (2015-2020)
  • Table 87. North America Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 88. North America Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 89. North America Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 90. United States Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 91. United States Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 92. United States Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 93. Canada Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 94. Canada Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 95. Canada Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 96. Mexico Refractory Multiple Myeloma Treatment, by Type USD Million (2015-2020)
  • Table 97. Mexico Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 98. Mexico Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2015-2020)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Refractory Multiple Myeloma Treatment: by Type(USD Million)
  • Table 110. Refractory Multiple Myeloma Treatment Immunomodulatory drugs (IMiDs) (Thalidomide (THAL), Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib) , by Region USD Million (2021-2026)
  • Table 111. Refractory Multiple Myeloma Treatment Cytotoxic agents , by Region USD Million (2021-2026)
  • Table 112. Refractory Multiple Myeloma Treatment High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT) , by Region USD Million (2021-2026)
  • Table 113. Refractory Multiple Myeloma Treatment Allogeneic Stem Cell Transplantation , by Region USD Million (2021-2026)
  • Table 114. Refractory Multiple Myeloma Treatment: by Distribution Channel(USD Million)
  • Table 115. Refractory Multiple Myeloma Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 116. Refractory Multiple Myeloma Treatment Cancer Institutes , by Region USD Million (2021-2026)
  • Table 117. Refractory Multiple Myeloma Treatment Ambulatory Surgical Centers , by Region USD Million (2021-2026)
  • Table 118. Refractory Multiple Myeloma Treatment Others , by Region USD Million (2021-2026)
  • Table 119. Refractory Multiple Myeloma Treatment: by Drug Class(USD Million)
  • Table 120. Refractory Multiple Myeloma Treatment Proteasome Inhibitor , by Region USD Million (2021-2026)
  • Table 121. Refractory Multiple Myeloma Treatment Anti-CD38 Monoclonal Antibody , by Region USD Million (2021-2026)
  • Table 122. Refractory Multiple Myeloma Treatment Alkylating Agents , by Region USD Million (2021-2026)
  • Table 123. Refractory Multiple Myeloma Treatment Others , by Region USD Million (2021-2026)
  • Table 124. South America Refractory Multiple Myeloma Treatment, by Country USD Million (2021-2026)
  • Table 125. South America Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 126. South America Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 127. South America Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 128. Brazil Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 129. Brazil Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 130. Brazil Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 131. Argentina Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 132. Argentina Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 133. Argentina Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 134. Rest of South America Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 135. Rest of South America Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 136. Rest of South America Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 137. Asia Pacific Refractory Multiple Myeloma Treatment, by Country USD Million (2021-2026)
  • Table 138. Asia Pacific Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 139. Asia Pacific Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 140. Asia Pacific Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 141. China Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 142. China Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 143. China Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 144. Japan Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 145. Japan Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 146. Japan Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 147. India Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 148. India Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 149. India Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 150. South Korea Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 151. South Korea Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 152. South Korea Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 153. Taiwan Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 154. Taiwan Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 155. Taiwan Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 156. Australia Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 157. Australia Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 158. Australia Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 162. Europe Refractory Multiple Myeloma Treatment, by Country USD Million (2021-2026)
  • Table 163. Europe Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 164. Europe Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 165. Europe Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 166. Germany Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 167. Germany Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 168. Germany Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 169. France Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 170. France Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 171. France Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 172. Italy Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 173. Italy Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 174. Italy Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 175. United Kingdom Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 176. United Kingdom Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 177. United Kingdom Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 178. Netherlands Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 179. Netherlands Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 180. Netherlands Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 181. Rest of Europe Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 182. Rest of Europe Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 183. Rest of Europe Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 184. MEA Refractory Multiple Myeloma Treatment, by Country USD Million (2021-2026)
  • Table 185. MEA Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 186. MEA Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 187. MEA Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 188. Middle East Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 189. Middle East Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 190. Middle East Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 191. Africa Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 192. Africa Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 193. Africa Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 194. North America Refractory Multiple Myeloma Treatment, by Country USD Million (2021-2026)
  • Table 195. North America Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 196. North America Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 197. North America Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 198. United States Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 199. United States Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 200. United States Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 201. Canada Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 202. Canada Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 203. Canada Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 204. Mexico Refractory Multiple Myeloma Treatment, by Type USD Million (2021-2026)
  • Table 205. Mexico Refractory Multiple Myeloma Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 206. Mexico Refractory Multiple Myeloma Treatment, by Drug Class USD Million (2021-2026)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Refractory Multiple Myeloma Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Refractory Multiple Myeloma Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Refractory Multiple Myeloma Treatment: by Drug Class USD Million (2015-2020)
  • Figure 7. South America Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 8. Asia Pacific Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 9. Europe Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 10. MEA Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 11. North America Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 12. Global Refractory Multiple Myeloma Treatment share by Players 2020 (%)
  • Figure 13. Global Refractory Multiple Myeloma Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Refractory Multiple Myeloma Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 17. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2020
  • Figure 18. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 20. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 22. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 23. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 24. Bristol Myers Squibb Company (Unite States) Revenue, Net Income and Gross profit
  • Figure 25. Bristol Myers Squibb Company (Unite States) Revenue: by Geography 2020
  • Figure 26. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 28. ONO PHARMACEUTICAL CO., LTD. (Japan) Revenue, Net Income and Gross profit
  • Figure 29. ONO PHARMACEUTICAL CO., LTD. (Japan) Revenue: by Geography 2020
  • Figure 30. Janssen Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Janssen Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 32. AbbVie Inc (United States) Revenue, Net Income and Gross profit
  • Figure 33. AbbVie Inc (United States) Revenue: by Geography 2020
  • Figure 34. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 35. Sanofi (France) Revenue: by Geography 2020
  • Figure 36. Global Refractory Multiple Myeloma Treatment: by Type USD Million (2021-2026)
  • Figure 37. Global Refractory Multiple Myeloma Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 38. Global Refractory Multiple Myeloma Treatment: by Drug Class USD Million (2021-2026)
  • Figure 39. South America Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 40. Asia Pacific Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 41. Europe Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 42. MEA Refractory Multiple Myeloma Treatment Share (%), by Country
  • Figure 43. North America Refractory Multiple Myeloma Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Takeda Pharmaceutical Company Limited (Japan)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline Plc (United Kingdom)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Bristol Myers Squibb Company (Unite States)
  • Amgen Inc. (United States)
  • ONO PHARMACEUTICAL CO., LTD. (Japan)
  • Janssen Pharmaceuticals, Inc. (United States)
  • AbbVie Inc (United States)
  • Sanofi (France)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation